Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO:...
TOKYO and CHERTSEY, September 24, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that The Committee for Medicinal Products for...
TOKYO, September 21, 2018 -Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that XOSPATA® Tablets 40 mg (generic name: gilteritinib), a...
TOKYO, September 20, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that roxadustat, an inhibitor of hypoxia ¬inducible factor...
TOKYO, September 18, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has launched Dafclir® Tablets 200 mg (generic name:...
TOKYO, September 14, 2018 –Gene Therapy Research Institution Co., Ltd. (head office: Kawasaki, Kanagawa; President: Katsuhito Asai, “GTRI”) and Astellas Pharma Inc. (TSE: 4503, head office:...
NEW YORK and TOKYO, August 22, 2018 –Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced amendments to the...
TOKYO and CAMBRIDGE, Mass August 21, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD ,...
TOKYO, CAMBRIDGE (UK), August 10, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,Ph.D., “Astellas”) and Quethera Limited (CEO: Peter Widdowson, Ph.D.,...
Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO:...
TOKYO and NEW YORK, July 13, 2018 –Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug...
BOTHELL, Wash., and TOKYO, July 9, 2018 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced...
TOKYO, July 2, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has received an approval for the marketing application of...
TOKYO, June 29, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that results from the pivotal Phase 3 PROSPER trial, which...
Tokyo, June 28, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been selected for the seventh consecutive year to be included in...
TOKYO, June 11, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it launched 40 mg XTANDI® (generic name enzalutamide) Tablets and 80...
TOKYO and BOTHELL, Wash. – June 3, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced...
Tokyo, May 31, 2018- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.) today announced that at the meeting of the Board of Directors held today, a resolution was adopted...
TOKYO, May 31, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has submitted an application for marketing approval of peficitinib...
Follow us
